• About Us
  • Contact Us
  • Home
  • Write for us
Today Headline
No Result
View All Result
  • breaking news today
    • Politics news
    • Sports
    • Science News
  • Entertainment News
  • Technology News
    • Automotive
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
  • breaking news today
    • Politics news
    • Sports
    • Science News
  • Entertainment News
  • Technology News
    • Automotive
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
No Result
View All Result
TodayHeadline
No Result
View All Result

An mRNA vaccine with a twist—it copies itself—protects against COVID-19 – Science

April 22, 2022
in Health News
0
An mRNA vaccine with a twist—it copies itself—protects against COVID-19 – Science

A third messenger RNA (mRNA) vaccine appears to have proved its worth against COVID-19. And although it is more than a year behind the Moderna and Pfizer-BioNTech vaccines now seen as gold standards, the new vaccine may come with significant advantages: easier storage, along with lower cost because its “self-amplifying” design allows for smaller doses.

Arcturus Therapeutics of San Diego, which staged a placebo-controlled trial of its candidate in more than 17,000 participants in Vietnam, announced yesterday in a press release that the vaccine had 55% efficacy against symptomatic COVID-19 and provided 95% efficacy against severe illness and death. “It’s a huge accomplishment that for the first time a self-amplifying RNA vaccine has been shown to be safe and effective,” says Deborah Fuller, a vaccinologist at the University of Washington School of Medicine who is an adviser to HDT Bio, which has its own self-amplifying COVID-19 mRNA vaccine in human studies.

Arcturus’s success may also help make mRNA vaccines more broadly accessible. Its candidate incorporates a freeze-drying process to transform the mRNA-filled solution into a powder that can be stored at room temperature, then rehydrated. This has far simpler cold-chain requirements than the conventional, liquid mRNA vaccines in use. And Vietnam’s Vinbiocare Biotechnology, which collaborated with Arcturus on the trial and has submitted the efficacy data to the country’s regulators for emergency use authorization, hopes to manufacture the product there.

The Pfizer-BioNTech and Moderna vaccines contain mRNA that codes for the SARS-CoV-2 spike protein. When the vaccines are injected, they deliver the mRNA to cells, which make copies of spike and then clear the foreign genetic material within a few days. Arcturus’s self-amplifying vaccine and others in development include enzymes from alphaviruses to repeatedly copy the genetic strand inside a cell and stay in the body for more than twice as long.

Some researchers have cautioned that self-amplifying vaccines cannot use an mRNA modification that is key to the Moderna and Pfizer-BioNTech vaccines: the replacement of the natural RNA building block uridine with pseudouridine. Studies have shown the swap leads to higher levels of the spike protein and lower production of immune chemicals called cytokines that can cause side effects. A conventional mRNA vaccine made by CureVac failed in an efficacy trial last year, and some scientists suggested this may have been because it didn’t use pseudouridine. But Arcturus says the efficacy findings refute those concerns. “It’s a big deal for the field,” says Pad Chivukula, the company’s chief scientific officer.

The trial, which began in August 2021, gave participants two doses, each containing 5 micrograms of the self-amplifying mRNA, spaced 28 days apart. The Pfizer-BioNTech and Moderna vaccines use 30-microgram and 100-microgram doses, respectively, for the first two shots.

Like most COVID-19 vaccinemakers with fresh efficacy trial results, Arcturus only released a peek at the findings. The bottom line against symptomatic infection—55% efficacy—is below the 90% to 95% seen in trials of the first two mRNA vaccines. But those vaccines faced the original SARS-CoV-2 virus. The Arcturus candidate, based on a similar strain, had to protect against the Delta and Omicron variants that were circulating in Vietnam during the trial, which have evolved dramatically from the ancestral strain, decreasing the power of vaccine-triggered antibodies. Fuller says the current real-world effectiveness of existing mRNA vaccines may be in the same ballpark. Of the 43 severe cases of COVID-19 recorded by Arcturus during the trial, only two were in the vaccinated group, and nine of the 10 people with COVID-19 who died received the placebo.

“These are indeed exciting results,” says chemist Benjamin Pierce, who is helping run a Ugandan trial of a self-amplifying mRNA COVID-19 vaccine made by Imperial College London. “The low dose used here—six to 20 times lower than approved RNA vaccines—further indicates that self-amplifying RNA technology has such potential. I look forward to seeing more of the data from the trial.”

Fuller says a self-amplifying mRNA COVID-19 vaccine ideally would replace the two primary doses, giving it an even clearer benefit over its conventional relatives. A booster months later might still be warranted, as is encouraged now for the current mRNA vaccines. But self-amplifying mRNAs could also lead to more durable immune responses, Fuller suggests.

When the Arcturus trial began, less than 15% of the eligible Vietnamese population had received even a single shot of a COVID-19 vaccine. Now, the figure is 80%, which raises the question of how the vaccine will perform in the vast majority of people who have already been vaccinated or naturally exposed to SARS-CoV-2. Arcturus hopes to soon launch a 2400-person trial to assess its value as a booster shot. This trial will aim to show the vaccine boosts antibody responses that other studies have shown correlate with protection—though no new COVID-19 vaccine has yet received authorization from strict U.S. or European regulators based on “immunobridging” data.

The Pfizer-BioNTech collaboration and Moderna have received intense criticism for not quickly sharing their manufacturing skills and intellectual property with developing countries, which have had relatively little access to their mRNA vaccines. Arcturus, in contrast, in August 2021 agreed to a technology transfer deal with Vinbiocare, which is building a plant in Hanoi to manufacture the vaccine.

But with much of the world vaccinated, the Arcturus vaccine may be making its debut too late, at least for primary vaccination. Chivukula is confident it will find a market in countries that have far lower vaccination rates than Vietnam and stresses it will be at “a price point that everyone can afford.”

Previous Post

This COVID-19 patient tested positive for the virus for 505 days – OregonLive

Next Post

Los Angeles REINSTATES masks on transit despite federal court striking down federal rules

Related Posts

Blood-based test could detect Alzheimer’s disease early, study suggests
Health News

Blood-based test could detect Alzheimer’s disease early, study suggests

Blood-based test could detect Alzheimer's...

Read more
Reuters reveals for China’s COVID policy, change comes in small increments
Health News

Reuters reveals for China’s COVID policy, change comes in small increments

Health06 November 2022, 6:52 pm....

Read more
FDA Panel Backs Shift Toward One-Dose COVID Shot
Health News

FDA Panel Backs Shift Toward One-Dose COVID Shot

Jan. 26, 2023 - A...

Read more
Poor literacy linked to worse mental health worldwide, study shows
Health News

Poor literacy linked to worse mental health worldwide, study shows

Credit: CC0 Public Domain People...

Read more
Riding Off the Deep End at the 2023 Dakar Rally
Health News

Riding Off the Deep End at the 2023 Dakar Rally

The mechanics, somehow, seem to...

Read more
Load More
Next Post
Los Angeles REINSTATES masks on transit despite federal court striking down federal rules

Los Angeles REINSTATES masks on transit despite federal court striking down federal rules

  • Trending
  • Comments
  • Latest
poker

Poker Strategies of Celebrity Players: Tips from the Pros

An Ava Max Song Led The Netherlands’ Far Right Party To Implode

An Ava Max Song Led The Netherlands’ Far Right Party To Implode

Espoma | Video: Stone Raised Bed Prep. with Summer Rayne Oakes || Flock Finger Lakes

Espoma | Video: Stone Raised Bed Prep. with Summer Rayne Oakes || Flock Finger Lakes

Keke Palmer Subtly Reveals the Sex of Her Baby

Keke Palmer Subtly Reveals the Sex of Her Baby

H.R. McMaster discusses Ukrainian President Volodymyr Zelenskyy's U.S. visit

The Gap Stock: Retail Nightmare That Will Not End (NYSE:GPS)

The Gap Stock: Retail Nightmare That Will Not End (NYSE:GPS)

Ban Djokovic’s dad from Open: Ukraine

Ban Djokovic’s dad from Open: Ukraine

Blood-based test could detect Alzheimer’s disease early, study suggests

Blood-based test could detect Alzheimer’s disease early, study suggests

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

H.R. McMaster discusses Ukrainian President Volodymyr Zelenskyy's U.S. visit

The Gap Stock: Retail Nightmare That Will Not End (NYSE:GPS)

The Gap Stock: Retail Nightmare That Will Not End (NYSE:GPS)

Ban Djokovic’s dad from Open: Ukraine

Ban Djokovic’s dad from Open: Ukraine

H.R. McMaster discusses Ukrainian President Volodymyr Zelenskyy's U.S. visit

The Gap Stock: Retail Nightmare That Will Not End (NYSE:GPS)

The Gap Stock: Retail Nightmare That Will Not End (NYSE:GPS)

Ban Djokovic’s dad from Open: Ukraine

Ban Djokovic’s dad from Open: Ukraine

  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2021 All rights are reserved Todayheadline

No Result
View All Result
  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2021 All rights are reserved Todayheadline

Go to mobile version